The global sepsis diagnostics market in terms of revenue was estimated to be worth $503 million in 2021 and is poised to reach $771 million by 2026, growing at a CAGR of 8.9% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The demand for sepsis diagnostic market products is expected to grow mainly due to factors such as the increasing public-private funding for sepsis diagnostic research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness.

Hospital-acquired infections (HAIs), also known as nosocomial infections, are a major cause of morbidity and mortality worldwide. The most common hospital-acquired infections (HAIs) are urinary tract infections, pneumonia, and sepsis. HAIs can lead to sepsis in immunocompromised patients, geriatric patients, and patients suffering from chronic illnesses. In the US, the incidence of sepsis among hospitalized patients is rising by 8.7% per year.

It is estimated that more than 1,000,000 cases of sepsis among hospitalised patients occur each year in the United States (Source: CDC, 2018). With the rapid increase in HAIs worldwide, the demand for sepsis diagnostic products is also expected to rise in the coming years. 

Based on technology, the biomarkers segment is expected to register the highest growth rate during the forecast period

Based on technology, the global sepsis diagnostics market is segmented into microbiology, molecular diagnostics, immunoassay, flow cytometry, microfluidics, and biomarkers. The biomarkers segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to various advantages offered by this technique in the diagnosis of sepsis and the growing need for early disease diagnosis.

North America accounted for the largest share of the sepsis diagnostics market

Geographically, the sepsis diagnostic market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to account for the largest share of the market. This can be attributed to the growing prevalence of sepsis, increasing incidence of hospital-acquired infections, fast adoption of high-end sepsis diagnostics devices, and rising government support for sepsis-related research. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155 

Some of the prominent players in the sepsis diagnostics market are bioMérieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland). Other players include T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), among others.